Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma  by Garcia, Jairo A. & Roberts, Lewis R.
International HepatologyPhase II, open-label study of brivanib as ﬁrst-line therapy in
patients with advanced hepatocellular carcinoma
Jairo A. Garcia, Lewis R. Roberts⇑
Fundación Valle Del Lili, Cali, Colombia; Hepatobiliary Neoplasia Clinic, Division of Gastroenterology and Hepatology, College of Medicine, Mayo
Clinic, Rochester, MN, USACOMMENTARY ON: vival rates for patients. Brivanib is an orally available selective
Phase II, open-label study of brivanib as ﬁrst-line therapy in
patients with advanced hepatocellular carcinoma. Park JW,
Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas M, Harris
R, Baudelet C, Walters I, Raoul JL. Clin Cancer Res 2011 Apr
1;17(7):1973–1983.
http://www.ncbi.nlm.nih.gov/pubmed/21349999
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V.
Liver cirrhosis is the major risk factor for the development of
Open access under CC BY-NC-ND license.hepatocellular carcinoma (HCC) and with the improving survival
of cirrhotic patients a rise in the number of HCC cases is being
reported worldwide. Early stage HCC can be treated with curative
intent by surgical resection, percutaneous ablation or liver trans-
plantation, but most HCCs are still diagnosed at an advanced
stage when curative approaches are not feasible and mortality
is consequently high [1]. Over the past few years, novel treatment
options based upon a new and improved understanding of the
molecular pathogenesis of HCC are being developed. Many of
these novel molecular therapies target growth and angiogenic
factors, their tyrosine kinase receptors, and their downstream
intracellular signal transduction and cell cycle control pathways.
Since the positive results from the large Phase III studies of the
receptor tyrosine kinase inhibitor, sorafenib [2,3], overall expec-
tations for further improvements in the outcomes of patients
with intermediate and advanced stage HCC have been height-
ened, and the door has been opened for the development and
testing of additional small molecule signaling pathway antago-
nists as targeted therapies for HCC with the goal of achieving sim-
ilar or better response rates and/or fewer adverse events.
The results of a Phase II open-label study of brivanib as ﬁrst-
line therapy in patients with unresectable, locally advanced, or
metastatic hepatocellular carcinoma have recently been pub-
lished [4]. Since HCC is highly vascularized, there is a strong
rationale for targeting key molecular pathways involved in tumor
neo-angiogenesis such as the FGF and VEGF signaling pathways
with the anticipation of a high response impact and better sur-Journal of Hepatology 20
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E-mail address: Roberts.lewis@mayo.edu (L.R. Roberts).dual inhibitor of the ﬁbroblast growth factor 2 (FGF-2) and vascu-
lar endothelial growth factor (VEGF) signaling pathways. Brivanib
not only has strong anti-angiogenic effects but also has potent
direct effects on tumor cells as shown in subcutaneous mouse
HCC xenograft models [5]. FGF is a potent angiogenic factor in
HCC and evidence suggests that the upregulation of alternate
pro-angiogenic signals such as the FGF pathway, may play a role
in tumor resistance to VEGF-targeted anti-angiogenic therapy [6].
Combined inhibition of the VEGF and FGF pathways may there-
fore be an ideal strategy to prevent or delay resistance to anti-
angiogenic therapy. Brivanib may also have efﬁcacy as a second
line therapy in HCC patients previously treated with sorafenib
[7].
The Phase II study of brivanib involved a mixed population of
55 patients who were two-thirds Asian (64%) and one-third Cau-
casian (33%). The 6-month progression-free survival (PFS) rate
was 18.2%, the median progression-free survival was 2.7 months,
and the median overall survival was 10 months. The PFS and 6-
month PFS were lower than anticipated at the study onset, when
the trial was planned to be deemed as having a positive outcome
if the 6-month PFS exceeded 35%. After the study was initiated,
the results of the Phase III study of sorafenib in the Asia-Paciﬁc
region were reported, showing a signiﬁcantly lower PFS of
2.8 months compared to the PFS observed in the treated arm of
the SHARP study. Considering that 64% of patients in the brivanib
Phase II study were Asian, the PFS of 2.7 months observed in this
study is likely comparable to the time to progression of
2.8 months observed in the Phase III study of sorafenib in
patients from the Asia-Paciﬁc region [3]. The median overall sur-
vival in this Phase II study of brivanib of 10 months is a remark-
able ﬁnding for a population with advanced stage HCC and is
encouraging compared to the median overall survival of
9.2 months observed in the Phase II study of sorafenib in patients
with advanced HCC and the median survival of 10.7 months
observed in the SHARP study [2,8]. The overall survival of
10 months is particularly notable given the high proportion of
Asian patients, since the overall survival seen in the Asia-Paciﬁc
sorafenib study was 6.5 months [3].
Although study patients tolerated brivanib with a manageable
safety proﬁle, eleven patients (21%) had to stop the medication
because of treatment-emergent adverse effects. Fatigue, hyper-
tension, and diarrhea were the most common adverse events
reported with incidences of 25%, 25%, and 23%, respectively.12 vol. 56 j 486–487
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The incidence of hand-foot syndrome in this study was 3.6%,
which is low compared to the rates reported in the SHARP [2]
and in the sorafenib Asian study where researchers found the
hand-foot syndrome in 8% and 10.7% respectively, leading to dose
reductions in 5% of patients in the SHARP and 11.4% in the sorafe-
nib Asian study [3]. These rates must, however, be considered
preliminary given the relatively small number of patients
enrolled in the study; more precise rates will have to await the
result of ongoing trials of brivanib in HCC.
Based on the results of this Phase II study, the investigators
conclude that brivanib shows promising antitumor activity and
a manageable safety proﬁle that warrants its evaluation for use
as a ﬁrst line therapy in patients with advanced stage HCC. The
early results of this study presumably contributed to the deci-
sions to proceed with Phase III randomized trials of brivanib com-
pared to sorafenib as ﬁrst line therapy and brivanib as an
adjuvant therapy after local palliative therapy in advanced stage
HCC. The results of these ongoing studies will help to better
deﬁne the role of brivanib as a targeted molecular therapy
against HCC.
The new era of targeted therapy for cancers has arrived for
HCC, but there is still much work to be done to deﬁne the speciﬁc
roles of the available and novel targeted agents and the patient
characteristics, disease stage, and combinations of treatments
that should be selected for optimal beneﬁt. These further
advances will be eagerly anticipated by the multidisciplinary
teams that care for these patients, and most of all, by our
patients.Journal of Hepatology 201Conﬂict of interest
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